TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05277896
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation
Study: NCT05277896
Drug: Etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation
Study: NCT00001991
Drug: Atovaquone
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00015691
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00015691
Drug: Rosiglitazone maleate
Normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04981704
Drug: Poziotinib
Normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poziotinib Tablets
Study: NCT04981704
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole Oral solution
Study: NCT04981704
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine Tablets
Study: NCT01039363
Drug: Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~* Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~* Gemtuzumab will be omitted in a consolidation schedule.~* Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT.
Study: NCT05387603
Drug: 177Lu-DOTATOC
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing.
Study: NCT05775874
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab:200mg Q3W
Study: NCT05135715
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.0 mg/kg IV every 2 weeks
Study: NCT05730712
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05730712
Drug: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Normalized name: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab 20000 U/10 ML-600 MG/10 ML-600 MG/10 ML Subcutaneous Solution
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT06412861
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine + 1 mg/kg propofol, Ramsey Sedation Score \> 4 will be targeted. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
Study: NCT06562647
Drug: SY001
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages
Study: NCT05163041
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
Study: NCT05934526
Drug: Seralutinib
Normalized name: Seralutinib
DrugBank: Seralutinib (DB18072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing seralutinib
Study: NCT06261203
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To investigate the efficacy of low dose aspirin for prevention of early pregnancy loss in women at high risk of preeclampsia.
Study: NCT05027100
Drug: Anlotinib Tislelizumab Irinotecan
Normalized name: Tislelizumab
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
Study: NCT05999240
Drug: Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]
Normalized name: pimavanserin tartrate 34 mg ORAL CAPSULE [NUPLAZID]
DrugBank: Pimavanserin (DB05316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo at Visit 2.
Study: NCT05959889
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive motelukast 10 mg for 4 cycles of AC.
Study: NCT05297968
Drug: Oseltamivir Phosphate For Oral Suspension/Tamiflu
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension/Tamiflu 75mg (6mg/ml,12.5ml)
Study: NCT05297968
Drug: Oseltamivir Phosphate For Oral Suspension
Normalized name: Oseltamivir Phosphate for Oral Suspension
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension 75mg (6mg/ml,12.5ml)
Study: NCT06541327
Drug: Chimeric Antigen Receptor
Normalized name: Chimeric antigen receptor
DrugBank: B7-H3-specific chimeric antigen receptor T cells (DB18567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T
Study: NCT05180422
Drug: AMG 510
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.
Study: NCT05180422
Drug: MVASI
Normalized name: Mvasi
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).
Study: NCT01675986
Drug: hydroxyzine
Normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg
Study: NCT01675986
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg
Study: NCT06759363
Drug: Sodium-Butyrate
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day of sodium-butyrate
Study: NCT04456439
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive diphenhydramine, 0.5-1 mg/kg, up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
Study: NCT06467513
Drug: Esketamine hydrochloride injection
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.
Study: NCT05048875
Drug: JNJ-64281802 (remaining high dose)
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1b, JNJ-64281802 (high dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days)
Study: NCT05048875
Drug: JNJ-64281802 (medium/low dose)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 2, JNJ-64281802 (low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days) AND JNJ-64281802 (medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days)
Study: NCT05048875
Drug: JNJ-64281802 (daily dosing regimen X)
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3, JNJ-64281802 (800-mg twice per day loading dose for 2 days/250-mg maintenance dose for 21 days)
Study: NCT05048875
Drug: JNJ-64281802 (weekly dosing regimen Y1)
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4, JNJ-64281802 (450-mg twice per day loading dose for 2 days/1200-mg maintenance dose weekly \[3 doses over 15 days\])
Study: NCT05048875
Drug: JNJ-64281802 (weekly dosing regimen Z2)
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 5, JNJ-64281802 (250-mg twice per day loading dose for 2 days/500-mg maintenance dose weekly \[3 doses over 15 days\])
Study: NCT04971005
Drug: Autologous Hematopoietic Stem Cell Transplantation
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Hematopoietic Stem Cell Transplantation
Study: NCT04971005
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg every 6 months continuously
Study: NCT04971005
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 mg/day for 5 consecutive days and again after 365 days for 3 days
Study: NCT04743557
Drug: DYN101
Normalized name: DYN101
DrugBank: DYN-101 (DB17921)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
Study: NCT05429294
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with HER2-positive advanced/metastatic breast cancer are treated with pyrotinib combined with trastuzumab and albumin paclitaxel in the first-line setting.
Study: NCT05872087
Drug: Nebulised Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: premedication by nebulised midazolam 0.3mg/kg in children undergoing lower abdominal surgeries
Study: NCT05811793
Drug: Tislelizumab and Bevacizumab
Normalized name: Tislelizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
Study: NCT00932763
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg tablets (Torrent Pharmaceuticals, India)
Study: NCT00932763
Drug: Norvasc
Normalized name: Norvasc
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg dose (Pfizer, USA)
Study: NCT04291937
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powder for concentrate for solution for infusion in 4 mg vials
Study: NCT06622239
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naltrexone 50mg for 6 weeks
Study: NCT06117657
Drug: Low dose KL-HIV-Tri01
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^11 vg/kg.
Study: NCT06117657
Drug: Middle dose KL-HIV-Tri01
Normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10\^11 vg/kg.
Study: NCT06117657
Drug: High dose KL-HIV-Tri01
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^12 vg/kg.
Study: NCT05497063
Drug: Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Study: NCT05881915
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
Study: NCT06341842
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapaglifloziin 10 mg 1 tab daily
Study: NCT04739358
Drug: Tepotinib
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
Study: NCT05914805
Drug: Clascoterone 5% solution
DrugBank: Clascoterone (DB12499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
Study: NCT06589635
Drug: ADC-189 and Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 1:~Day 1, fasting condition, 45 mg ADC189, administered orally~Part 2:~Day 22, 200 mg itraconazole bid, taken orally after meals. Day 23-Day 25, 200 mg itraconazole was taken orally after meals. Day 26, 45 mg ADC-189 and 200 mg itraconazole was taken orally after meals. Day 27-Day 39, 200 mg itraconazole was taken orally after meals.
Study: NCT05755087
Drug: Tegavivint
Normalized name: Tegavivint
DrugBank: Tegavivint (DB17109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06604442
Drug: Flotufolastat (18F)
Normalized name: Flotufolastat (18F)
DrugBank: Flotufolastat F-18 (DB17851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron emission tomography (PET)
Study: NCT06604442
Drug: piflufolastat (18F)
Normalized name: piflufolastat (18F)
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron emission tomography (PET)
Study: NCT05830799
Drug: Drug Drug Interaction
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated
Study: NCT05364177
Drug: 68Ga-Pentixather
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.
Study: NCT05364177
Drug: 68Ga-Pentixafor
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
Study: NCT05229380
Drug: Saccharin test
Normalized name: Saccharin
DrugBank: Saccharin (DB12418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.
Study: NCT04703335
Drug: Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation
Normalized name: povidone-iodine
DrugBank: Fica (DB03384)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.
Study: NCT05854082
Drug: Lidocaine 2% Polyampoule
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three intervention conditions in a repeated measures design - lidocaine; no perturbation, candy (lollipop)
Study: NCT05544916
Drug: XC221
Normalized name: XC221
DrugBank: XC221 (DB16503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day, for 5 days
Study: NCT05767905
Drug: PF-06821497 Treatment A
Normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-06821497 administered under fasting conditions.
Study: NCT05767905
Drug: PF-06821497 Treatment B
Normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-06821497 administered under fasting conditions.
Study: NCT05767905
Drug: PF-06821497 Treatment C
Normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-06821497 administered under fasting conditions.
Study: NCT05767905
Drug: PF-06821497 Treatment D
Normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-06821497 administered under fasting conditions.
Study: NCT05767905
Drug: PF-06821497 Treatment E
Normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-06821497 administered after low fat meal
Study: NCT05767905
Drug: PF-06821497 Treatment F
Normalized name: F
DrugBank: PF-06821497 (DB14799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of PF-06821497 administered after high fat meal.
Study: NCT05173298
Drug: atezolizumab plus bevacizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
Study: NCT06301685
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. once a day.
Study: NCT06587451
Drug: JPB898 (Induction and Maintenance)
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction and Maintenance: Intravenous (IV)
Study: NCT06587451
Drug: Opdivo-EU (Induction)
Normalized name: Opdivo
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: Intravenous (IV)
Study: NCT06114836
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole will be the PPI prescribed for 4 weeks.
Study: NCT06485557
Drug: sintilimab plus platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy
Study: NCT06485557
Drug: sintilimab plus platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
Study: NCT06485557
Drug: sintilimab plus platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.
Study: NCT06587451
Drug: Opdivo-US (Induction)
Normalized name: Opdivo
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: Intravenous (IV)
Study: NCT06587451
Drug: Yervoy-EU (Induction)
Normalized name: Yervoy
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: Intravenous (IV)
Study: NCT06587451
Drug: Opdivo-EU (Maintenance)
Normalized name: Opdivo
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance: Intravenous (IV)
Study: NCT05616728
Drug: EDP-235
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT06377410
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant with stable COPD who received N-Acetylcysteine for 1 month
Study: NCT05598255
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During standard anaesthetic management: IV administration of dexamethasone (0,5mg/kg, with a maximum dose of 5mg).
Study: NCT05153304
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
Study: NCT05132920
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21